Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.
Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 AAAAI Annual Meeting.
Research presented at AAAAI 2026 suggests GLP-1 RAs may provide clinical benefits for asthma management in patients with excess body weight.
Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results